Guselkumab vs Risankizumab for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had Crohn's disease for at least 12 weeks, confirmed by tests like X-rays, biopsies, or a camera exam.
- Your Crohn's is moderate to severe, based on a symptom score between 220 and 450.
- You have active inflammation in your small or large intestine seen during a colonoscopy, with ulcers of a certain size and area.
- You have not had recent surgery (bowel removal within 6 months or other major surgery within 3 months) before starting the study.
- You do not have complications like a blocked intestine, an abscess, a draining stoma, or a fistula that might need surgery soon.
- You do not have cancer or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This trial tests whether risankizumab can help people with a type of Crohn's disease where the intestine becomes narrowed (fibrostenotic) and causes symptoms like cramping or vomiting. The goal is to see if the drug can reduce inflammation and improve these blockages.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.